Perioperative/Postoperative ComplicationsMINSSNCT03436238
Myocardial Injury in Noncardiac Surgery in Sweden
An observational study of Perioperative/Postoperative Complications and Risk Factor, Cardiovascular, run by Linkoeping University at 7 sites in Sweden.
Trial summary
The purpose of this multicentre, prospective, observational study is to identify robust biochemical markers that predict adverse cardiovascular outcomes and mortality in patients undergoing major abdominal surgery. Read more about this study
- Who is it for?
- Ages 50 years and older
- Conditions the study is for
- Perioperative/Postoperative Complications, Risk Factor, Cardiovascular
- How many people
- 1,269 participants
- Where
- 7 sitesSweden
- Study dates
- 15 May 2017to 31 Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients scheduled for elective, major abdominal surgery at participating centres, requiring general anaesthesia, and requiring at least one overnight stay.
Who may be able to join
- Adult patients undergoing elective, major abdominal surgery*.
- (Major abdominal surgery requiring general anaesthesia, and requiring at least one overnight stay. Major abdominal surgery is defined as those classified as major OR major/complex by the Surgical Outcome Risk Tool (SORT) (www.sortsurgery.com).
- In essence major surgery is one that penetrates and exposes a body cavity or produces a substantial impairment of physical or physiologic function or involves extensive dissection or transection. Examples of a major abdominal surgery include, but are not limited to, any procedure involving a laparotomy or laparoscopic procedures of the stomach, duodenum, small and large intestine and rectum. It also includes but is not limited to procedures on the reproductive system (total abdominal hysterectomy, salpingo-oophorectomy) and genitourinary system (nephrectomy, cystectomy).)
Who cannot join
- Patient not fulfilling inclusion study criteria above and/or clinician refusal and/or non-eligible as defined below.
- Patients undergoing the following surgical procedures will NOT be eligible:
- transplantation
- trauma
- endocrine
- vascular
Show all 13Show fewer
- endovascular
- The presence of any one of the following will also lead to exclusion of the patient:
- ACS at presentation (clinical assessment or documentation)
- New or decompensated congestive heart failure at presentation (clinical assessment or documentation)
- Documented severe aortic stenosis (valve area < 1cm2)
- Reduced LVEF (<40%); if no LVEF is available, it will be assumed to be >40%
- Inability to follow the procedures of the study, e.g. due to language problems, dementia, etc. of the participant
Trial locations and contacts
7 sites in 1 country.
7 sites in 1 country
Sweden7 sites
Eskilstuna Hospital
Eskilstuna
Ryhov County Hospital
Jönköping
Kristianstad KRYH Hospital
Kristianstad, Skåne County
Department of Anaesthesia and Intensive Care, Linkoeping University Hospital, Region Östergötland
Linköping, Östergötland County, 50185
Skane University Hospital Lund
Lund
Skane University Hospital Malmö
Malmö
Vrinnevi Hospital
Norrköping
About this study
Official title: Myocardial Injury in Noncardiac Surgery in Sweden (MINSS) Study: Multi-centre, Observational Cohort Study of Patients Undergoing Elective, Major Abdominal Surgery.
The purpose of this multicentre, prospective, observational study is to identify robust biochemical markers that predict adverse cardiovascular outcomes and mortality in patients undergoing major abdominal surgery.
Read the detailed description
Inclusion Adults at least 50 years old undergoing elective, major or major/complex abdominal surgery defined according to the Surgical Outcome Risk Tool (www.sortsurgery.com), requiring general anaesthesia and at least one overnight stay. Exclusion Patients with acute coronary syndromes, new or decompensated heart failure at presentation, documented severeaortic stenosis, severely reduced ejection fraction (<40%) and inability to follow the procedures of the study or lack of capacity to give informed consent. Transplantation, trauma, endocrine, vascular and endovascular surgical procedures will also be excluded due to their distinct risk profiles compared with the intended population. Outcome The composite endpoint is all-cause mortality at 30 days and MACCE, the latter defined as nonfatal cardiac arrest, acute MI, congestive heart failure, new cardiac arrhythmia, angina and stroke. Secondary endpoints are 365-day all-cause mortality and MACCE. Data collection Relevant clinical and peri-operative data for example comorbidities, RCRI, ASA-PS score, type and length of surgery, blood loss and intra-operative lowest blood pressure will be collected.
Plasma levels of hsTnT, NTproBNP, Copeptin, MR-proADM and CT-proET1 will be measured at five sampling points: pre-operatively, immediately postoperatively, and on Days 1 to 3 postoperatively or until discharge. Data on MACCE will be obtained from patient records and structured telephone interviews at 30 and 365 days by assessors blinded to the results of the biomarker analyses.
Statistics Based on an assumed incidence of MINS of 10%(1) and 365-day mortality in the non-MINS group of 11% (estimate based on current data from the Swedish Perioperative Registry), the required sample size to detect an effect size of 10% is 1142. To account for drop-outs and missing data, we will recruit up to 1600 patients.
Receiver operating curve analysis will be used to determine the optimal threshold of each biomarker in predicting mortality/MACCE. The net reclassification index will be used to assess if biomarkers confer added value to the RCRI for the classification of MACCE.
A multivariable Cox proportional hazard models will be used to test the independent prognostic value of biomarkers. The sample size allows for adjustment of the following prespecified variables, selected on the basis of clinical plausibility and prior evidence: age, sex, ASA-PS class, RCRI, Charlson Comorbidity Index, length and type of surgery, presence of intra-operative hypotension, pre-operative creatinine and haemoglobin, biomarkers (alone and in combination). An independent statistical analysis will be conducted after recruitment of 600 patients to assess the frequency of outcomes and missing data, after which the sample size may be adjusted.
NOTE: An independent assessment by the Data Safety and Monitoring Board (DSMB) specifically addressing a revision of the sample size found that a total of 1269-1334 participants would be required for the study. This was based on a lower than expected rate of missing data (7.6% at DSMB assessment vs. expected 33% during study planning).
We therefore revised the sample size to 1269 (-1334) participants on 2 September 2019.
UPDATE 26 Feb 2022:
This study (including outcomes up to 30d after surgery) has been published: https://www.bjanaesthesia.org/article/S0007-0912(21)00649-8/fulltext
UPDATE 11 Jan 2023:
The following preplanned substudies are ongoing:
- Effect of myocardial injury (MINS) on quality of recovery in patients undergoing major abdominal procedures in Sweden. The aim of the study is to investigate the postoperative quality of recovery (QoR) and the disability-free survival (DFS) among patients undergoing major abdominal surgery with and without perioperative myocardial injury in non-cardiac surgery (MINS). Our hypothesis is that patients with MINS have a poorer QoR and reduced DFS at short- and long-term follow-up. P:nested, cohort sub study within the Myocardial Injury in Noncardiac Surgery in Sweden (MINSS, NCT 03436238) study including patients from 2 participating hospitals E: Acute perioperative myocardial injury, defined as an increase in hsTnT≥14 ng L-1 above baseline value and measured at days 0-3 postoperatively. C: No perioperative myocardial injury O:Postoperative Quality of Recovery (QoR-15) scores at 7-10 days, 30-days and 1-year after surgery compared to the baseline. Secondary outcome is Disability Free Survival at 30-days and 1-year after surgery. DFS is defined as alive and WHODAS score of ≤ 25%.
- The Effect of Perioperative Haemoglobin Decrease on Long-term Surgical Outcomes. The aim of this study is to investigate the effect of perioperative decrease in haemoglobin (Hb) level on the long-term outcomes of patients undergoing major abdominal surgery. P:We will include all patients enrolled in the MINSS study if there are available post-operative Hb measurement(s) and 1-year follow-up data. E:perioperative decrease in Hb level is the exposure variable of this study. C:various strata of perioperative Hb decrease O:The primary outcome of this study is the composite of one-year all-cause mortality and major adverse cardiovascular and cerebrovascular events (MACCE). The secondary outcome is 30-day post-operative complications defined as MACCE, re-operation, anastomosis leakage, post-operative infections or bleeding, renal or respiratory failure and pulmonary embolism
- Incidence and trajectories of subclinical postoperative acute kidney injury (sPO-AKI), postoperative acute kidney injury (PO-AKI) and postoperative acute kidney disease (PO-AKD) among patients undergoing elective, major non-cardiac surgery. The primary aim of this study is to investigate the incidence of subclinical postoperative acute kidney injury (sPO-AKI), postoperative acute kidney injury (PO-AKI) and postoperative acute kidney disease (PO-AKD) and the trajectory of sPO-AKI, among patients undergoing elective, major non-cardiac surgery. Secondary aims are to evaluate the relationship between sPO-AKI and major adverse kidney events by 30 days (MAKE30) and all-cause mortality at 30 days postoperatively as well as chronic kidney disease (CKD) at one year postoperatively. P: nested, cohort sub study within the Myocardial Injury in Noncardiac Surgery in Sweden (MINSS, NCT 03436238) study including patients from 2 participating hospitals E:Serum creatinine (sCr) measured preoperatively and days 0-3 postoperatively, sCr obtained from patient charts between day 4-365 and occurrence of ICD codes N17.9, N18.X, N19.9 and N99.9 between day 0-365. C: no increase in sCr O: The primary outcome is incidence of sPO-AKI, PO-AKI and PO-AKD, as defined below. The secondary outcomes are 30-day all-cause mortality, MAKE 30, and CKD at 1-year post-surgery
- The predictive role of MR-proADM for postoperative infections after major non-cardiac surgery: a sub-study of MINSS The primary aim of this study is to assess if mid-regional pro-adrenomedullin (MR-proADM) adds value to standard biomarkers in predicting postoperative infection following major non-cardiac surgery.
The secondary aim is to assess the prognostic value of MR-proADM for 30-day and 12-month all-cause mortality.
P:Predefined, nested sub-study of the Myocardial Injury in Noncardiac Surgery in Sweden project (MINSS, NCT 03436238) including patients from Linköping University and Norrköping Hospitals.
E: Increased plasma values of MR-proADM measured preoperatively and days 0-3 postoperatively.
C: No increase in plasma MR-proADM O:10-day postoperative infections Postoperative infections are defined as the presence of any of the following: superficial wound infections, deep wound infections, body cavity infections, pneumonias, urinary tract infections, bloodstream infections and sepsis as outlined in the European Perioperative Clinical Outcome (EPCO) 2014 definitions.
Secondary outcome:
30-day all-cause mortality. 12-month all-cause mortality. 10-day postoperative sepsis.
- Phenotypes of perioperative myocardial injury and impact on long-term outcomes among patients undergoing major elective non-cardiac surgery.
The aim of this study is to evaluate how different phenotypes of myocardial injury may impact the long-term outcomes among patients undergoing major elective non-cardiac surgery. P: Pre-planned, sub-study within the Myocardial Injury in Noncardiac Surgery in Sweden (MINSS), a multicenter, prospective cohort study with available long-term follow-up data.
E:Patients are classified to 1) isolated preoperative increases (>99th URL) in hs-cTnT (likely chronic), 2) perioperative changes (postop-preop >99th URL) with normal preoperative hs-cTnT, 3) perioperative changes (postop-preop >99th URL) with increased preoperative hs-cTnT, 4) only postoperative increases (99th URL between 2 postoperative measurements.
C: no pre-, peri- or postoperative hs-cTnT increases O: The primary outcomes are all-cause mortality and major adverse cardiovascular and cerebrovascular events (MACCE) at longest follow up. MACCE is the composite of non-fatal cardiac arrest, myocardial infarction, new onset angina, new onset heart failure, new onset arrythmia (atrial fibrillation, atrial flutter, or second- or third-degree atrioventricular block), non-fatal cardiac arrest, and cerebrovascular insult (stroke and transient ischemic attack).
The secondary outcomes are the individual components of the MACCE definition described above, cardiac death (according to StEP COMPAC), and extracardiac adverse events (sepsis, acute kidney injury, pulmonary embolism) at longest follow up.
- Incidence and outcome of perioperative blood transfusion in patients undergoing major non-cardiac surgery in Sweden. aims to investigate the incidence and outcome of perioperative blood transfusion in patients undergoing major non-cardiac surgery in Sweden. Proposed research questions will include:
- What is the incidence of perioperative transfusion of blood and blood products?
- What is the relationship between preoperative anaemia and intraoperative transfusion?
- What is the relationship between preoperative anaemia and post-operative transfusion?
- What is the relationship between intra- and post-operative transfusions and mortality, major adverse cardiovascular and cerebrovascular events and postoperative infections? P:nested cohort in the MINSS study including 3 participating centres E:perioperative blood transfusion C:no perioperative blood transfusion O:The primary outcome of this study is the transfusion of any blood product within the first 3 days of surgery. A co-primary outcome is the composite of all-cause mortality, major adverse cardiovascular and cerebrovascular events, and post-operative infection at 30 days post-surgery.
- Keywords
- Perioperative, Biomarkers, Troponin, Prodrenomedullin, Endothelin, Perioperative Complications, Myocardial injury, Major adverse cardiovascular events
- Medical subject headings
- Postoperative Complications
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| MINSS cohort | Adult patients >= 50 years old undergoing elective, major, abdominal surgery requiring at least one overnight stay in hospital. Major abdominal surgery is defined as those classified as major OR major/complex by the Surgical Outcome Risk Tool (SORT) (www.sortsurgery.com). |
What is being measured
The primary outcome is the main question the study is designed to answer.
30-day mortality
All-cause mortality at 30 days post-surgery.
Measured: 30 days post surgery
30-day MACCE
Major adverse cardio- cerebrovascular events (MACCE) at 30 days post-surgery.
Measured: 30 days post surgery
Secondary outcomes (2)
12-month mortality
All-cause mortality at 12 months post-surgery.
Measured: 12 months post surgery
12-month MACCE
Major adverse cardio- cerebrovascular events (MACCE) at 12 months post-surgery.
Measured: 12 months post surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Feb 2018
- Study start15 May 2017
- Primary completion31 Mar 2020
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Perioperative/Postoperative ComplicationsStudies of the same condition, open and under way.
- More trials run by Linkoeping UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,269 participants (actual)
Sponsor and investigators
- Lead sponsor
- Linkoeping University
- Sponsor type
- Other government
- Collaborators
- Region Östergötland, Medical Research Council of Southeast Sweden
- Responsible party
- Principal investigator, Michelle Chew, Linkoeping University
- Investigators
- Michelle S Chew, MBBS, PhD, Principal investigator, Linkoeping University and Region Östergötland
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03436238
- Sponsor's protocol ID
- MINSS
- Acronym
- MINSS
- Status last verified
- Mar 2026
- First submitted
- 10 Feb 2018
- Last updated
- 17 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Falt M, Ahman R, Hammarskjold F, Lyckner S, Jawad M, Andersson U, Fredrikson M, Sperber J, Elander L, De Geer L, Didriksson H, Jonsson C, Andersson H, Chew MS. Long-term outcomes of time-dependent phenotypes of perioperative myocardial injury☆. BJA Open. 2025 Jun 4;14:100422. doi: 10.1016/j.bjao.2025.100422. eCollection 2025 Jun.
PubMed 40529719Chew MS, Puelacher C, Patel A, Hammarskjold F, Lyckner S, Kollind M, Jawad M, Andersson U, Fredrikson M, Sperber J, Johnsson P, Elander L, Zeuchner J, Linhardt M, De Geer L, Rolander WG, Gagno G, Didriksson H, Pearse R, Mueller C, Andersson H. Identification of myocardial injury using perioperative troponin surveillance in major noncardiac surgery and net benefit over the Revised Cardiac Risk Index. Br J Anaesth. 2022 Jan;128(1):26-36. doi: 10.1016/j.bja.2021.10.006. Epub 2021 Nov 29.
PubMed 34857357
Study at a glance
From the registry record, last updated by the sponsor on 17 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Myocardial Injury in Noncardiac Surgery in Sweden (MINSS) Study: Multi-centre, Observational Cohort Study of Patients Undergoing Elective, Major Abdominal Surgery.
- ClinicalTrials.gov ID
- NCT03436238
- Acronym / sponsor ID
- MINSS / MINSS
- Keywords
- Perioperative, Biomarkers, Troponin, Prodrenomedullin, Endothelin, Perioperative Complications, Myocardial injury, Major adverse cardiovascular events
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 1,269 participants (actual)
- Lead sponsor
- Linkoeping UniversityOther government
- Collaborators
- Region Östergötland, Medical Research Council of Southeast Sweden
- Study start
- 15 May 2017 (actual)
- Primary completion
- 31 Mar 2020 (actual)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 19 Feb 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this multicentre, prospective, observational study is to identify robust biochemical markers that predict adverse cardiovascular outcomes and mortality in patients undergoing major abdominal surgery.
Detailed description
Inclusion Adults at least 50 years old undergoing elective, major or major/complex abdominal surgery defined according to the Surgical Outcome Risk Tool (www.sortsurgery.com), requiring general anaesthesia and at least one overnight stay. Exclusion Patients with acute coronary syndromes, new or decompensated heart failure at presentation, documented severeaortic stenosis, severely reduced ejection fraction (<40%) and inability to follow the procedures of the study or lack of capacity to give informed consent. Transplantation, trauma, endocrine, vascular and endovascular surgical procedures will also be excluded due to their distinct risk profiles compared with the intended population. Outcome The composite endpoint is all-cause mortality at 30 days and MACCE, the latter defined as nonfatal cardiac arrest, acute MI, congestive heart failure, new cardiac arrhythmia, angina and stroke. Secondary endpoints are 365-day all-cause mortality and MACCE. Data collection Relevant clinical and peri-operative data for example comorbidities, RCRI, ASA-PS score, type and length of surgery, blood loss and intra-operative lowest blood pressure will be collected.
Plasma levels of hsTnT, NTproBNP, Copeptin, MR-proADM and CT-proET1 will be measured at five sampling points: pre-operatively, immediately postoperatively, and on Days 1 to 3 postoperatively or until discharge. Data on MACCE will be obtained from patient records and structured telephone interviews at 30 and 365 days by assessors blinded to the results of the biomarker analyses.
Statistics Based on an assumed incidence of MINS of 10%(1) and 365-day mortality in the non-MINS group of 11% (estimate based on current data from the Swedish Perioperative Registry), the required sample size to detect an effect size of 10% is 1142. To account for drop-outs and missing data, we will recruit up to 1600 patients.
Receiver operating curve analysis will be used to determine the optimal threshold of each biomarker in predicting mortality/MACCE. The net reclassification index will be used to assess if biomarkers confer added value to the RCRI for the classification of MACCE.
A multivariable Cox proportional hazard models will be used to test the independent prognostic value of biomarkers. The sample size allows for adjustment of the following prespecified variables, selected on the basis of clinical plausibility and prior evidence: age, sex, ASA-PS class, RCRI, Charlson Comorbidity Index, length and type of surgery, presence of intra-operative hypotension, pre-operative creatinine and haemoglobin, biomarkers (alone and in combination). An independent statistical analysis will be conducted after recruitment of 600 patients to assess the frequency of outcomes and missing data, after which the sample size may be adjusted.
NOTE: An independent assessment by the Data Safety and Monitoring Board (DSMB) specifically addressing a revision of the sample size found that a total of 1269-1334 participants would be required for the study. This was based on a lower than expected rate of missing data (7.6% at DSMB assessment vs. expected 33% during study planning).
We therefore revised the sample size to 1269 (-1334) participants on 2 September 2019.
UPDATE 26 Feb 2022:
This study (including outcomes up to 30d after surgery) has been published: https://www.bjanaesthesia.org/article/S0007-0912(21)00649-8/fulltext
UPDATE 11 Jan 2023:
The following preplanned substudies are ongoing:
- Effect of myocardial injury (MINS) on quality of recovery in patients undergoing major abdominal procedures in Sweden. The aim of the study is to investigate the postoperative quality of recovery (QoR) and the disability-free survival (DFS) among patients undergoing major abdominal surgery with and without perioperative myocardial injury in non-cardiac surgery (MINS). Our hypothesis is that patients with MINS have a poorer QoR and reduced DFS at short- and long-term follow-up. P:nested, cohort sub study within the Myocardial Injury in Noncardiac Surgery in Sweden (MINSS, NCT 03436238) study including patients from 2 participating hospitals E: Acute perioperative myocardial injury, defined as an increase in hsTnT≥14 ng L-1 above baseline value and measured at days 0-3 postoperatively. C: No perioperative myocardial injury O:Postoperative Quality of Recovery (QoR-15) scores at 7-10 days, 30-days and 1-year after surgery compared to the baseline. Secondary outcome is Disability Free Survival at 30-days and 1-year after surgery. DFS is defined as alive and WHODAS score of ≤ 25%.
- The Effect of Perioperative Haemoglobin Decrease on Long-term Surgical Outcomes. The aim of this study is to investigate the effect of perioperative decrease in haemoglobin (Hb) level on the long-term outcomes of patients undergoing major abdominal surgery. P:We will include all patients enrolled in the MINSS study if there are available post-operative Hb measurement(s) and 1-year follow-up data. E:perioperative decrease in Hb level is the exposure variable of this study. C:various strata of perioperative Hb decrease O:The primary outcome of this study is the composite of one-year all-cause mortality and major adverse cardiovascular and cerebrovascular events (MACCE). The secondary outcome is 30-day post-operative complications defined as MACCE, re-operation, anastomosis leakage, post-operative infections or bleeding, renal or respiratory failure and pulmonary embolism
- Incidence and trajectories of subclinical postoperative acute kidney injury (sPO-AKI), postoperative acute kidney injury (PO-AKI) and postoperative acute kidney disease (PO-AKD) among patients undergoing elective, major non-cardiac surgery. The primary aim of this study is to investigate the incidence of subclinical postoperative acute kidney injury (sPO-AKI), postoperative acute kidney injury (PO-AKI) and postoperative acute kidney disease (PO-AKD) and the trajectory of sPO-AKI, among patients undergoing elective, major non-cardiac surgery. Secondary aims are to evaluate the relationship between sPO-AKI and major adverse kidney events by 30 days (MAKE30) and all-cause mortality at 30 days postoperatively as well as chronic kidney disease (CKD) at one year postoperatively. P: nested, cohort sub study within the Myocardial Injury in Noncardiac Surgery in Sweden (MINSS, NCT 03436238) study including patients from 2 participating hospitals E:Serum creatinine (sCr) measured preoperatively and days 0-3 postoperatively, sCr obtained from patient charts between day 4-365 and occurrence of ICD codes N17.9, N18.X, N19.9 and N99.9 between day 0-365. C: no increase in sCr O: The primary outcome is incidence of sPO-AKI, PO-AKI and PO-AKD, as defined below. The secondary outcomes are 30-day all-cause mortality, MAKE 30, and CKD at 1-year post-surgery
- The predictive role of MR-proADM for postoperative infections after major non-cardiac surgery: a sub-study of MINSS The primary aim of this study is to assess if mid-regional pro-adrenomedullin (MR-proADM) adds value to standard biomarkers in predicting postoperative infection following major non-cardiac surgery.
The secondary aim is to assess the prognostic value of MR-proADM for 30-day and 12-month all-cause mortality.
P:Predefined, nested sub-study of the Myocardial Injury in Noncardiac Surgery in Sweden project (MINSS, NCT 03436238) including patients from Linköping University and Norrköping Hospitals.
E: Increased plasma values of MR-proADM measured preoperatively and days 0-3 postoperatively.
C: No increase in plasma MR-proADM O:10-day postoperative infections Postoperative infections are defined as the presence of any of the following: superficial wound infections, deep wound infections, body cavity infections, pneumonias, urinary tract infections, bloodstream infections and sepsis as outlined in the European Perioperative Clinical Outcome (EPCO) 2014 definitions.
Secondary outcome:
30-day all-cause mortality. 12-month all-cause mortality. 10-day postoperative sepsis.
- Phenotypes of perioperative myocardial injury and impact on long-term outcomes among patients undergoing major elective non-cardiac surgery.
The aim of this study is to evaluate how different phenotypes of myocardial injury may impact the long-term outcomes among patients undergoing major elective non-cardiac surgery. P: Pre-planned, sub-study within the Myocardial Injury in Noncardiac Surgery in Sweden (MINSS), a multicenter, prospective cohort study with available long-term follow-up data.
E:Patients are classified to 1) isolated preoperative increases (>99th URL) in hs-cTnT (likely chronic), 2) perioperative changes (postop-preop >99th URL) with normal preoperative hs-cTnT, 3) perioperative changes (postop-preop >99th URL) with increased preoperative hs-cTnT, 4) only postoperative increases (99th URL between 2 postoperative measurements.
C: no pre-, peri- or postoperative hs-cTnT increases O: The primary outcomes are all-cause mortality and major adverse cardiovascular and cerebrovascular events (MACCE) at longest follow up. MACCE is the composite of non-fatal cardiac arrest, myocardial infarction, new onset angina, new onset heart failure, new onset arrythmia (atrial fibrillation, atrial flutter, or second- or third-degree atrioventricular block), non-fatal cardiac arrest, and cerebrovascular insult (stroke and transient ischemic attack).
The secondary outcomes are the individual components of the MACCE definition described above, cardiac death (according to StEP COMPAC), and extracardiac adverse events (sepsis, acute kidney injury, pulmonary embolism) at longest follow up.
- Incidence and outcome of perioperative blood transfusion in patients undergoing major non-cardiac surgery in Sweden. aims to investigate the incidence and outcome of perioperative blood transfusion in patients undergoing major non-cardiac surgery in Sweden. Proposed research questions will include:
- What is the incidence of perioperative transfusion of blood and blood products?
- What is the relationship between preoperative anaemia and intraoperative transfusion?
- What is the relationship between preoperative anaemia and post-operative transfusion?
- What is the relationship between intra- and post-operative transfusions and mortality, major adverse cardiovascular and cerebrovascular events and postoperative infections? P:nested cohort in the MINSS study including 3 participating centres E:perioperative blood transfusion C:no perioperative blood transfusion O:The primary outcome of this study is the transfusion of any blood product within the first 3 days of surgery. A co-primary outcome is the composite of all-cause mortality, major adverse cardiovascular and cerebrovascular events, and post-operative infection at 30 days post-surgery.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| MINSS cohort | – | –Adult patients >= 50 years old undergoing elective, major, abdominal surgery requiring at least one overnight stay in hospital. Major abdominal surgery is defined as those classified as major OR major/complex by the Surgical Outcome Risk Tool (SORT) (www.sortsurgery.com). |
Who may qualify
- Ages
- 50 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients scheduled for elective, major abdominal surgery at participating centres, requiring general anaesthesia, and requiring at least one overnight stay.
Key inclusion criteria (3 listed)
- Adult patients undergoing elective, major abdominal surgery*.
- (Major abdominal surgery requiring general anaesthesia, and requiring at least one overnight stay. Major abdominal surgery is defined as those classified as major OR major/complex by the Surgical Outcome Risk Tool (SORT) (www.sortsurgery.com).
- In essence major surgery is one that penetrates and exposes a body cavity or produces a substantial impairment of physical or physiologic function or involves extensive dissection or transection. Examples of a major abdominal surgery include, but are not limited to, any procedure involving a laparotomy or laparoscopic procedures of the stomach, duodenum, small and large intestine and rectum. It also includes but is not limited to procedures on the reproductive system (total abdominal hysterectomy, salpingo-oophorectomy) and genitourinary system (nephrectomy, cystectomy).)
Key exclusion criteria (13 listed)
- Patient not fulfilling inclusion study criteria above and/or clinician refusal and/or non-eligible as defined below.
- transplantation
- trauma
- endocrine
- vascular
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
30-day mortality
Time frame: 30 days post surgery
All-cause mortality at 30 days post-surgery.
30-day MACCE
Time frame: 30 days post surgery
Major adverse cardio- cerebrovascular events (MACCE) at 30 days post-surgery.
2 secondary outcomes
12-month mortality
Time frame: 12 months post surgery
12-month MACCE
Time frame: 12 months post surgery
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Mar 2026.
- Derived from this study: PubMed 40529719Falt M, Ahman R, Hammarskjold F, Lyckner S, Jawad M, Andersson U, Fredrikson M, Sperber J, Elander L, De Geer L, Didriksson H, Jonsson C, Andersson H, Chew MS. Long-term outcomes of time-dependent phenotypes of perioperative myocardial injury☆. BJA Open. 2025 Jun 4;14:100422. doi: 10.1016/j.bjao.2025.100422. eCollection 2025 Jun.
- Derived from this study: PubMed 34857357Chew MS, Puelacher C, Patel A, Hammarskjold F, Lyckner S, Kollind M, Jawad M, Andersson U, Fredrikson M, Sperber J, Johnsson P, Elander L, Zeuchner J, Linhardt M, De Geer L, Rolander WG, Gagno G, Didriksson H, Pearse R, Mueller C, Andersson H. Identification of myocardial injury using perioperative troponin surveillance in major noncardiac surgery and net benefit over the Revised Cardiac Risk Index. Br J Anaesth. 2022 Jan;128(1):26-36. doi: 10.1016/j.bja.2021.10.006. Epub 2021 Nov 29.
- Individual participant dataSharing planned: Undecided
Related trials for Perioperative/Postoperative Complications
Not yet recruitingObservational study
Systematic Intraoperative Cell Salvage in On-Pump Cardiac Surgery Within a Mature Patient Blood Management Programme
Cardiac Surgical Procedures, Blood Transfusion
Not yet recruiting
Prediction and Prevention of Postoperative Mortality and Morbidity
Dementia, Postoperative Delirium (POD)
Active, not recruitingObservational study
Association of POCD With Circulating Biomarkers in Patients Undergoing TUR of Bladder Tumor
Cognitive Decline, Urinary Bladder Cancer
Active, not recruiting
Prehabilitation in Pancreatic Surgery
Pancreatic Cancer, Periampullary Cancer
Not yet recruitingPhase 4
Perioperative Dutasteride for Hemorrhage Control in Bipolar TURP Under Anticoagulation.
Benign Prostatic Hyperplasia, Postoperative Hemorrhage
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Michelle S Chew, MBBS, PhD principal investigator
Linkoeping University and Region Östergötland
7 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Perioperative/Postoperative Complications and Risk Factor, Cardiovascular, run by Linkoeping University at 7 sites in Sweden.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 17 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 7 sites in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
30-day mortality (time frame: 30 days post surgery). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03436238, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Mar 2026.